Voxel‐based specific regional analysis system for Alzheimer’s disease utility as a screening tool for unrecognized cognitive dysfunction of elderly patients in diabetes outpatient clinics: Multicenter retrospective exploratory study

Aims/Introduction An efficient screening strategy for identification of cognitive dysfunction remains a clinical issue in the management of elderly adults with diabetes. A magnetic resonance imaging voxel‐based specific regional analysis system for Alzheimer’s disease (VSRAD) has been developed as an automated brain morphometry system that includes the hippocampus. We carried out a multicenter retrospective study to evaluate the utility of VSRAD for screening cognitive dysfunction in diabetes outpatient clinics. Materials and Methods We enrolled patients with diabetes aged >65 years who underwent brain magnetic resonance imaging scans for the purpose of a medical checkup between November 2018 and May 2019. Patients who were already suspected or diagnosed with mild cognitive impairment and/or dementia as well as those with a history of cerebrovascular disease were excluded. Results A total of 67 patients were enrolled. Five patients were diagnosed with mild cognitive impairment or dementia (clinical cognitive dysfunction). Patients with clinical cognitive dysfunction showed a significantly higher z‐score in VSRAD analysis (2.57 ± 0.47 vs 1.15 ± 0.55, P
We evaluated the utility of the voxel‐based specific regional analysis system of Alzheimer's disease, an automated brain morphometry system that includes the hippocampus, for screening unrecognized cognitive dysfunction in elderly patients with diabetes. This is the first report to assess the association between hippocampal atrophy and cognitive dysfunction by an automated voxel‐based morphometry system in clinical diabetes practice. The results suggest that the voxel‐based specific regional analysis system of Alzheimer's disease can be useful for early identification of cognitive dysfunction in the elderly with diabetes.